Skip to main content
OpenTrials
Completed

NCT Number: NCT04171349

Articaine vs Dexmedetomidine Supplemented Articaine

The aim of this study to test efficacy of adding dexmedetomidine to articaine on sensory, motor and duration of analgesia during hemodialysis fistula creation under ultrasound guided supraclavicular block

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Failure Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

25 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Ain Shams University hosptal

Cairo, Abbasya, Egypt

About this study

Adult fifty patient with chronic renal failure on hemodialysis, scheduled for arteriovenous fistula creation under ultrasound guided supraclavicular block. Patients were randomly allocated in two group. The articaine group (group A) received 40 ml articaine hydrochloride 2% and articaine-dexmedetomidine group (group AD) received 40 ml. Of articaine 2% mixed with dexmedetomidine (1micogram/kg)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult patient with chronic renal failure on hemodialysis scheduled for radiocephalic fistula creation

Exclusion criteria

  • Allergy to local anesthetics.
  • Infection at the site of needle insertion.
  • Those having international normalized ratio more than 1.5.
  • Coagulopathy.
  • Neuromuscular, or severe hepatic or severe pulmonary disease.
  • Those having epilepsy.
  • Patients who refused to participate.

Treatment and study plan

Articaine

Drug

Vial

Dexmedetomidine

Drug

Vial

Primary outcomes

  1. Duration of sensory block

    Time frame: 24 hours

    Sensory block time tested by pinprick test measured in minute

  2. Duration of motor block

    Time frame: 24 hours

    Motor block time tested by Bromage scale measured in minutes

Secondary outcomes

  1. Duration of analgesia

    Time frame: 24 hours

    Measured by visual analog scale score 4

Other outcomes

  1. Sedation

    Time frame: 24 hours

    Measured by Ramsay sedation scale score 3

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Articaine and Dexmedetomidine - Supplemented Articaine for Arteriovenous Fistula Creation Under Ultrasound- Guided Supraclavicular Block

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Nov 20, 2019
Registry last updated
Nov 20, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.